10-Q: Clover Health Reports Q2 Loss Amid Soaring Medical Costs

Clover Health Investments, Corp. reported a net loss for Q2 2025, driven by a significant increase in medical claims incurred despite strong revenue and membership growth.

Summary

• Total revenues increased by 34.1% to $477.6 million for the three months ended June 30, 2025, compared to $356.3 million in the prior year period.
• Net medical claims incurred surged by 52.2% to $378.0 million for the three months ended June 30, 2025, up from $248.3 million in the same period last year.
• The company reported a net loss of $10.6 million for the three months ended June 30, 2025, a significant shift from a net income of $7.4 million in the prior year period.
• Insurance members at period end grew by approximately 32% to 106,323 at June 30, 2025, compared to 80,261 at June 30, 2024.
• The Benefits Expense Ratio (net) increased to 88.4% for the three months ended June 30, 2025, from 76.1% in the comparable prior year period.
• Adjusted EBITDA decreased to $17.1 million for Q2 2025, down from $36.2 million in Q2 2024.
• Net cash used in operating activities from continuing operations was $10.9 million for the six months ended June 30, 2025, a reversal from $79.7 million provided in the prior year period.
• The SEC investigation related to certain disclosures and the Hindenburg Article has concluded, with the Staff not intending to recommend an enforcement action against the company.
• Securities class action lawsuit settled for $22 million, with $19.5 million funded by insurance proceeds.
• Shareholder derivative actions settled, requiring corporate governance enhancements and a $2.5 million payment for plaintiffs' counsel fees, with no monetary payment from the company beyond that.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant deterioration in profitability metrics (net loss, lower Adjusted EBITDA, higher Benefits Expense Ratio) and a swing to negative operating cash flow, despite strong top-line revenue and membership growth. While legal uncertainties have been resolved and a new SaaS initiative launched, the core business's escalating medical costs are a major concern.

Positives

• Strong revenue growth of 34.1% for the quarter and 33.7% for the six months, driven by increased membership.
• Significant membership growth of approximately 32% at period end, indicating successful enrollment efforts.
• Adjusted SG&A as a percentage of Total revenues improved to 17.3% for Q2 2025 from 20.1% in Q2 2024, demonstrating improved operational leverage.
• Faster claims processing speed, with 81.7% of current year medical claims paid as a percentage of current year Net medical claims incurred for H1 2025, up from 67.6% in H1 2024, leading to a decrease in unpaid claims liability.
• The SEC investigation has concluded with no enforcement action recommended against the company, resolving a significant regulatory overhang.
• Securities class action and shareholder derivative lawsuits have been settled, removing substantial legal uncertainties and potential liabilities.
• Launch of Counterpart Health, a Software-as-a-Service (SaaS) and Tech Enabled Services Solution, aiming for new potential growth and high-margin business opportunities with low startup costs by leveraging existing technology.

Negatives

• Shift from a net income of $7.4 million in Q2 2024 to a net loss of $10.6 million in Q2 2025.
• Net medical claims incurred increased by 52.2% in Q2 2025, significantly outpacing the 34.3% growth in premiums earned, net.
• The Benefits Expense Ratio (net) worsened considerably to 88.4% in Q2 2025 from 76.1% in Q2 2024, indicating higher medical costs relative to premiums.
• Adjusted EBITDA decreased by over 50% from $36.2 million in Q2 2024 to $17.1 million in Q2 2025.
• Net cash used in operating activities from continuing operations for the six months ended June 30, 2025, was $10.9 million, a significant deterioration from $79.7 million provided in the prior year period.
• Increase in Part D cost sharing due to changes arising from the Inflation Reduction Act contributed to higher medical claims.
• Less favorable prior period developments impacted current year medical claims compared to the prior year.

Risks

• Changes in government healthcare policy, including CMS's intention to significantly increase the volume of Risk Adjustment Data Validation (RADV) audits, could materially adversely affect business, results of operations, and financial condition.
• The ability to maintain or improve Star Ratings is crucial for financial performance, and failure to do so could negatively impact the business.
• Fluctuations in the price of Class A common stock and continued compliance with Nasdaq's listing requirements pose ongoing risks.
• General economic conditions and uncertainty, including persistent high inflation and fluctuating interest rates, could impact financial results.
• The company's ability to effectively manage its beneficiary base and provider network is critical for controlling medical costs and maintaining quality of care.
• Future capital requirements may necessitate additional equity or debt financing, which could be dilutive to existing investors or include restrictive covenants.

Future Outlook

The company expects its cash, cash equivalents, investments, and current projections of cash flows to be sufficient to meet projected operating and regulatory requirements for the next 12 months. Future capital requirements will depend on business growth, opportunities, challenges, or unforeseen circumstances, and additional equity or debt financing may be required. The company is evaluating the financial impact of the recently signed One Big Beautiful Bill Act (OBBBA) on its federal corporate income tax system.

Management Comments

• Our vision is to empower every physician with the technology to identify, manage, and treat chronic diseases earlier.
• Our strategy is to improve the care of people with Medicare, develop wide physician networks, and provide technology to help empower physicians.
• We believe the use of Clover Assistant and related data insights allows us to improve clinical decision-making through a highly scalable platform.
• We strongly believe in providing our members provider choice, and we consider our PPO plans to be our flagship insurance product.
• The longer a member is enrolled in one of our insurance plans, the more data we collect and synthesize and the more actionable insights we generate, which we believe leads to better care delivery and improved identification, documentation, and management of members' chronic conditions, helping to lower PMPM medical claim expenses.
• Management believes that the current reserves for unpaid claims are adequate based on currently available information.

Industry Context

Clover Health operates in the highly competitive and rapidly changing Medicare Advantage market. The increase in Part D cost sharing due to the Inflation Reduction Act reflects broader regulatory impacts on the healthcare insurance industry. The company's focus on technology-driven care management through Clover Assistant and its new Counterpart Health SaaS offering aligns with a growing industry trend towards leveraging AI and data analytics to improve patient outcomes and manage costs in value-based care models. The exit from the ACO REACH Program indicates a strategic shift away from certain government-sponsored risk-sharing models, potentially in response to evolving program dynamics or internal strategic priorities.

Comparison to Industry Standards

• The significant increase in the Benefits Expense Ratio (BER) to 88.4% for Q2 2025 is notably higher than typical target BERs for profitable Medicare Advantage plans, which often aim for ratios in the low to mid-80s. For example, leading MA players like UnitedHealthcare (Optum) or Humana often report medical loss ratios (MLRs) in the 80-85% range, indicating Clover's medical costs are consuming a larger portion of premiums.
• The swing to negative operating cash flow for the six months ended June 30, 2025, contrasts with more established and profitable MA providers who typically generate substantial positive cash flow from operations, reflecting challenges in converting premium revenue into sustainable cash generation.
• While membership growth of 32% is robust and indicative of strong market penetration, the inability to translate this growth into improved net income or Adjusted EBITDA suggests that the underlying unit economics (PMPM medical claims vs. PMPM premiums) are deteriorating, which is a critical concern compared to peers who balance growth with profitability.

Corporate Governance

Legal Proceedings

• The SEC investigation related to certain disclosures and the Hindenburg Article has concluded, with the Staff not intending to recommend an enforcement action against the company.
• Securities class action lawsuit (Bond v. Clover Health Investments, Corp. et al.) was settled for $22 million, with $19.5 million funded by insurance proceeds, and dismissed with prejudice on October 3, 2023.
• Shareholder derivative actions (e.g., Furman v. Garipalli, et al.) were settled, requiring corporate governance enhancements and a $2.5 million payment for plaintiffs' counsel fees, with final court approval on July 11, 2024.
• The company intends to oppose any efforts by its insurers to recoup insurance proceeds advanced for the securities litigation.

Related Party Transactions

• CarePoint Health System (IJKG Opco LLC, Hudson Hospital Opco, LLC, Hoboken University Medical Center Opco LLC) was previously a related party due to Vivek Garipalli's ultimate control. Expenses incurred were $2.6 million (Q2 2025) and $4.4 million (H1 2025). As of May 22, 2025, following CarePoint Health's emergence from bankruptcy and transfer of control to Hudson Regional Hospital, it is no longer deemed a related party.
• Medical Records Exchange, LLC (d/b/a Credo) is a related party due to Vivek Garipalli's indirect ownership. Expenses incurred were $0.1 million (Q2 2025) and $0.3 million (H1 2025).
• Thyme Care, Inc. is a related party due to Vivek Garipalli's board membership and equity interest. Expenses incurred were $1.5 million (Q2 2025) and $4.2 million (H1 2025). The company holds a less than 5% equity interest in Thyme Care, valued at $3.9 million at June 30, 2025.

Stakeholder Impact

• Shareholders: Negative impact from net loss, declining Adjusted EBITDA, and negative operating cash flow, potentially leading to share price pressure. However, resolution of legal proceedings and strategic initiatives like Counterpart Health offer long-term potential.
• Employees: Increase in headcount due to membership growth, but prior restructuring (10% workforce reduction in April 2023) indicates past workforce adjustments.
• Customers (Medicare Advantage members): Continued membership growth suggests satisfaction with plans. Focus on Clover Assistant aims to improve care quality and lower costs for members.
• Creditors: Liquidity position is deemed sufficient for the next 12 months, but a swing to negative operating cash flow and potential future capital raises could be a point of monitoring.
• Providers: Continued engagement through Clover Assistant and expansion of Counterpart Assistant to external providers, aiming to empower physicians with data-driven insights.

Next Steps

• Company is evaluating the impact of ASU 2023-09 (Income Taxes) on its consolidated financial statements and related disclosures, effective for fiscal years beginning after December 15, 2024.
• Company is evaluating the impact of ASU 2024-03 (Expense Disaggregation Disclosures) on its consolidated financial statements and related disclosures, effective for annual reporting periods beginning after December 15, 2026.
• Company is evaluating the financial impact of the One Big Beautiful Bill Act (OBBBA) signed on July 4, 2025, on its US federal corporate income tax system.

Key Dates

Recommendation

Despite strong revenue and membership growth, the significant increase in net medical claims incurred, the sharp rise in the Benefits Expense Ratio, and the swing to a net loss and negative operating cash flow indicate a deteriorating core business profitability. While legal uncertainties have been resolved, the fundamental financial performance trends are concerning. A seasoned investor would likely view the escalating costs relative to premiums as a major red flag, suggesting a 'sell' recommendation until there is clear evidence of improved cost management and a return to sustainable profitability in the core insurance operations.

Keywords

Medicare Advantage, Health Insurance, Healthcare Technology, Clover Assistant, MA Plans, Q2 Earnings, SEC Filing, Medical Loss Ratio, HealthTech, Insurance, Managed Care